AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/28/2026

1. SPY
2. AKAM
3. COST
4. META
5. ZS
6. NVDA
7. AWK
8. DRI
9. ULS
10. CRL

Go back to AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026
(NASDAQ: ABCL) Delayed: 12.70 +0.05 (0.40%)
Previous Close $12.65    52 Week High $ 
Open $12.74    52 Week Low $ 
Day High $12.93    P/E N/A 
Day Low $12.29    EPS $ 
Volume 3,382,858